cyclophosphamide (Cytoxan, Neosar, Procytox {Canadian}) [CPM, CTX, CYT, NSC 26271]

From Aaushi
Jump to navigation Jump to search

Introduction

Tradename: Cytoxan.

Indications

Contraindications

pregnancy category = d

Dosage

Tabs: 50 mg.

Pharmacokinetics

elimination via liver

elimination via kidney

1/2life = 3-12 hours

elimination by hemodialysis = +

Monitor

clinical & laboratory monitoring every 4-8 weeks[10]

Adverse effects

Drug interactions

Laboratory

Mechanism of action

More general terms

Additional terms

Component of

References

  1. The Pharmacological Basis of Therapeutics, 9th ed. Gilman et al, eds. Permagon Press/McGraw Hill, 1996
  2. Saunders Manual of Medical Practice, Rakel (ed), WB Saunders, Philadelphia, 1996, pg 792
  3. Mayo Internal Medicine Board Review, 1998-99, Prakash UBS (ed) Lippincott-Raven, Philadelphia, 1998, pg 856-57
  4. Drug Information & Medication Formulary, Veterans Affairs, Central California Health Care System, 1st ed., Ravnan et al eds, 1998
  5. Kaiser Permanente Northern California Regional Drug Formulary, 1998
  6. Harrison's Principles of Internal Medicine, 14th ed. Fauci et al (eds), McGraw-Hill Inc. NY, 1998, pg 529, 533
  7. Geriatric Dosage Handbook, 6th edition, Selma et al eds, Lexi-Comp, Cleveland, 2001
  8. 8.0 8.1 Deprecated Reference
  9. 9.0 9.1 Pagnoux C, Quemeneur T, Ninet J et al Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: Results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis & rheumatology 2015 Apr; 67:1117. PMID: https://www.ncbi.nlm.nih.gov/pubmed/25693055
  10. 10.0 10.1 10.2 10.3 10.4 10.5 Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015
  11. 11.0 11.1 Talar-Williams C, Hijazi YM, Walther MM et al Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med. 1996 Mar 1;124(5):477-84. PMID: https://www.ncbi.nlm.nih.gov/pubmed/8602705
  12. Perez EA, Suman VJ, Davidson NE et al Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol. 2008 Mar 10;26(8):1231-8 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18250349

Database